# Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac

> **NCT05205096** · PHASE1,PHASE2 · COMPLETED · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 480 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant novel coronavirus vaccine (CHO cells)

## Key facts

- **NCT ID:** NCT05205096
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-10
- **Primary completion:** 2022-06-03
- **Final completion:** 2022-07-31
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2023-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05205096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05205096, "Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05205096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*